Synthesis and assessment of 99mTc chelate-conjugated alendronate for development of specific radiopharmaceuticals

Cancer Biotherapy and Radiopharmaceuticals

Volumn 24, Issue 2, 2009, Pages 209-214

  Shukla, Gauri ^a,b   Tiwari, Anjani K ^a   Sinha, Deepa ^a,b   Srivastava, Rakesh ^c   Cahndra, Hairsh ^a   Mishra, Anil K ^a  

^a INSTITUTE OF NUCLEAR MEDICINE AND ALLIED SCIENCES   (India)

^b UNIVERSITY OF DELHI   (India)

^c INDIAN INSTITUTE OF TECHNOLOGY DELHI   (India)

Author keywords

Biodistribution; Bisphosphonates; Radiochemistry; Scintigraphy

Indexed keywords

3 INDOLECARBALDEHYDE; ALDEHYDE DERIVATIVE; ALENDRONIC ACID TECHNETIUM TC 99M; MEDRONATE TECHNETIUM TC 99M; RADIOPHARMACEUTICAL AGENT; SOLVENT; UNCLASSIFIED DRUG; ALENDRONIC ACID; DIAGNOSTIC AGENT; DRUG DERIVATIVE; INDOLE DERIVATIVE; INDOLE-3-CARBALDEHYDE; TECHNETIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE; BONE CELL; DRUG CLEARANCE; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IMAGING; INFRARED SPECTROSCOPY; ISOTOPE LABELING; KIDNEY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MOUSE; NONHUMAN; POLYMERIZATION; PRIORITY JOURNAL; THIN LAYER CHROMATOGRAPHY; ULTRAVIOLET SPECTROSCOPY; ANIMAL; BAGG ALBINO MOUSE; CELL LINE; CHEMISTRY; INFRARED SPECTROPHOTOMETRY; METABOLISM; RABBIT; SCINTISCANNING; SYNTHESIS; TISSUE DISTRIBUTION;

ALENDRONATE; ANIMALS; BONE AND BONES; CELL LINE; HUMANS; INDOLES; MICE; MICE, INBRED BALB C; RABBITS; RADIOPHARMACEUTICALS; SPECTROPHOTOMETRY, INFRARED; TECHNETIUM; TISSUE DISTRIBUTION;

EID: 66249135975     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2008.0551     Document Type: Article

References (38)

1. Marks SC, Jr, Odgren PR. Structure and development of the skeleton. In: Bilezikian JP, Raisz LG, Rodan EA, eds. Principles of Bone Biology, 2nd ed., 2-vol set. San Diego: Academic Press, 2002: 3.
2. Odgren PR, Martin TJ. Therapeutic approaches to bone diseases. Science 2000; 289: 1508.
3. Ducy P, Zhang R, Geoffroy V, et al. A transcriptional activator of osteoblast differentiation. Cell 1997; 89: 747. (Pubitemid 27516177)
4. Takahashi N, Udagawa N, Takami M, Suda T. Cells of bone: Osteoclast generation. In: Bilezikian JP, Raisz LG, Rodan EA, eds. Principles of Bone Biology, 2nd ed., 2-vol set. San Diego: Academic Press, 2002: 109.
5. Fleisch H. Bisphosphonates: Mechanisms of action. Endocr Rev 1998; 19: 80. (Pubitemid 29122075)
6. Liberman UA, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis: The Alendronate Phase III Osteoporosis Treatment Study Group. NEMJ 1995; 333: 1437.
7. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996; 348: 1535. (Pubitemid 26411651)
8. McClung M, Clemmesen B, Daifotis A, et al. Alendronate prevents postmenopausal bone loss in women without osteoporosis: A double-blind randomized, controlled trial. Alendronate Osteoporosis Prevention Study Group. Ann Intern Med 1998; 128: 253.
9. Hosking D, Chilvers CED, Christiansen C, et al. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. N Engl J Med 1998; 338: 485. (Pubitemid 28103131)
10. Adami S, Passeri M, Orolani S, et al. Effects of oral alendronate and intranasal salmon calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis. Bone 1995; 17: 383.
11. Chesnut CH, McClung MR, Ensrud KE, et al. Alendronate treatment of the postmenopausal osteoporotic woman: Effect of multiple dosages on bone mass and bone remodeling. Am J Med 1995; 99: 144.
12. Devogelaer JP, Broll H, Correa-Rotter R, et al. Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis. Bone 1996; 18: 141. (Pubitemid 26092594)
13. Tucci JR, Tonino RP, Emkey RD, et al. Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis. Am J Med 1996; 101: 488. (Pubitemid 126335969)
14. Karpf DB, Shapiro DR, Seeman E, et al. Prevention of nonvertebral fractures by alendronate: A meta-analysis. The Alendronate Osteoporosis Treatment Study Groups. JAMA 1997; 277: 1159.
15. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial. JAMA 1998; 280: 2077. (Pubitemid 29014065)
16. Bergstrom JD, Bostedor RG, Masarachia PJ, et al. Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase. Arch Biochem Biophys 2000; 373: 231. (Pubitemid 30046509)
17. Bisaz S, Jung A, Fleisch H. Uptake by boul of pyrophosphate, diphosphonates, and their technetium derivatives. Clin Sci Mol Med 1978; 54; 265. (Pubitemid 8286494)
18. Jung A, Bisaz S, Fleisch H. The binding of pyrophosphate and two diphosphonates by hydroxyapatite crystals. Calcif Tissue Res 1973; 11: 269.
19. 99mTc-polyphosphate. Nucl Med 1974; 15: 1057.
20. Fitton A, McTavish D. Pamidronate: A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs 1991; 41: 289. (Pubitemid 121000771)
21. Francis MD, Ferguson DL, Tofe AJ, et al. Comparative evaluation of three diphosphonates: In-vitro adsorption (C- 14 labeled) and in-vivo osteogenic uptake (Tc-99m complexed). Nucl Med 1980; 21: 1185. (Pubitemid 11196766)
22. Mühlbauer RC. In: Bijvoet OLM, Fleisch HA, Canfield RE, Russell RGG, eds. Bisphosphonate on Bones. Amsterdam: Elsevier 1995: 171.
23. Jones AG, Francis MD, Davis MA. Bone scanning: Radionuclidic reaction mechanisms. Semin Nucl Med 1976; 6: 3.
24. Rodan GA, Fleisch HJ. Bisphosphonates: Mechanisms of action. Clin Invest 1996; 97: 2692. (Pubitemid 26197084)
25. Dufau C, Benramdane M, Leroux Y, et al. Phosphorous, sulfur silicon. Relat Elem 1995; 107: 145.
26. Kubicek V, Vojtísek P, Rudovsky J, et al. Complexes of divalent transitional met al.s with bis (amino methyl) phosphonic acid in aqueous solution and in solid state. Dalton Trans 2003; 20: 3927.
27. 99mTc-labeled phosphate and phosphonate agents for skelet al. imaging. Semin Nucl Med 1976; 6: 19.
28. 99mTc-MDP. Nucl Med Biol 1997; 24: 27. (Pubitemid 27145594)
29. Volkert WA, Edwards B, Simon J, et al. Int J Radiat Appl Instrum B 1986; 13: 31.
30. 99mTc-DPD, and 99mTc-HDP for the detection of bone metastases. Eur J Nucl Med 1983; 8: 118.
31. Vorne M, Vahatalo S, Lantto T. A clinical comparison of Tc- 99m DPD and two Tc-99m MDP agents. Eur J Nucl Med 1983; 8: 395.
32. Lin WY, Lin CP, Yeh SJ, et al. Rhenium-188 hydroxyethylidene diphosphonate: A new generator-produced radiotherapeutic drug of potential value for the treatment of bone metastases. Eur J Nucl Med 1997; 24: 590.
33. Goeckeler WF, Edwards B, Volkert WA, et al. Skelet al. localization of samarium-153 chelates: Potential therapeutic bone agents. J Nucl Med 1987; 28: 495. (Pubitemid 17074172)
34. Hamdy NA, Papapoulos SE. The palliative management of skelet al. metastases in prostate cancer: Use of bone-seeking radionuclides and bisphosphonates. Semin Nucl Med 2001; 31: 62. (Pubitemid 32060653)
35. De Klerk JMH, Van Dijk A, Van Rijk PP, et al. Pharmacokinetics of rhenium-186 after administration of Re-186-HEDP to patients with bone metastases. Nucl Med 1991; 32: 1082.
36. Maxon HR, III, Deutsch EA, Thomas SR, et al. Re-186 (Sn) HEDP for treatment of multiple metastatic foci in bone: Human biodistribution and dosimetric studies [published erratum appears in Radiology]. Radiology 1988; 166: 501.
37. Sinha D, Tiwari AK, Singh S, et al. Synthesis, characterization, and biological activiy of Schiff base analogues of indole-3-carboxaldehyde. Eur J Med Chem 2007; 43: 160.
38. Tiwari AK, Singh VK, Bajpai A, et al. Synthesis and biological properties of 4- (3H) -quinazolone derivatives. Eur J Med Chem 2007; 42: 1234. (Pubitemid 47238542)